Clinical trials: Herpes Simplex Type II
Melanoma
OH2 Injection in Combination With HX008 for Melanoma.
This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma.
- Trial name
- NCT04616443
- Testing
- OH2 injection, HX008 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
HIV/AIDS, HSV-2 Infection
Cash Transfer to Adolescent Girls and Young Women to Reduce Sexual Risk Behavior - an Impact Evaluation
Vulnerability to HIV infection in Adolescent Girls and Young Women (AGYW) is mainly influenced by structural factors which mediate through sexual risk behavior.
- Trial name
- CARE (NCT03597243)
- Testing
- Cash Transfer
- Where
- Tanzania
- Volunteers
- 3,120 people
- Sponsor
- National Institute for Medical Research, Tanzania
Genital Herpes
HSV-2 Shedding Resolution After Acyclovir Treatment
The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated…
- Trial name
- NCT00495573
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Genital Herpes, HSV-2 Infection
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence.
- Trial name
- NCT03146403
- Testing
- GEN-003, Matrix-M2, 0.9% normal saline
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Genocea Biosciences, Inc.
Herpes Simplex
Herpevac Neonatal Substudy
The purpose of this study to look at the antibodies (proteins from the body's infection fighting system) in the blood of babies delivered by women who are participants in the Herpevac Trial for Women, and who were vaccinated with…
- Trial name
- NCT00138320
- Where
- 5 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HSV-2 Infection, HIV Infections
Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa
The purpose of this study is to evaluate the impact of the new South African Department of Basic Education (DBE) sexuality and HIV education program that uses scripted lesson plans and supporting activities and will be…
- Conditions
- HSV-2 Infection, HIV Infections, Pregnancy Related
- Trial name
- NCT04205721
- Testing
- School-based sexuality and HIV prevention scripted lesson plans
- Where
- South Africa
- Volunteers
- 23,061 people
- Sponsor
- University of North Carolina, Chapel Hill
Genital Herpes Simplex Type 2
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
Randomized, double-blind, placebo-controlled, dose escalation study. There will be 3 cohorts of patients defined by the antigen dose (10, 30 or 100 µg of each antigen), and within each cohort, patients will be randomized at a…
- Trial name
- NCT01667341
- Testing
- GEN-003 with Matrix M-2, GEN-003
- Where
- 7 sites in United States
- Volunteers
- 143 people
- Sponsor
- Genocea Biosciences, Inc.
Genital Herpes, HIV Infection
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1…
- Trial name
- NCT00527618
- Testing
- valacyclovir, acyclovir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
HSV-2 Infection, PreTerm Birth
Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes
Preterm delivery (PTD), together with low birthweight (LBW), is the leading cause of infant death and illness, affecting 500,000 births with annual medical costs of more than $26 billion in the U.S. each year.
- Conditions
- HSV-2 Infection, PreTerm Birth, Pregnancy Complications
- Trial name
- PCORIHSV (NCT02986802)
- Where
- United States
- Volunteers
- 89,132 people
- Sponsor
- Kaiser Permanente
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in…
- Trial name
- NCT06698575
- Testing
- ABI-1179
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Genital Herpes Simplex Type 2
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2…
- Trial name
- NCT05432583
- Testing
- BNT163
- Where
- 6 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.
- Trial name
- NCT00362297
- Testing
- acyclovir, valacyclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Washington
Human Immunodeficiency Virus, Herpes Simplex
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
The purpose of this study is to compare the levels of immune and inflammatory markers among HIV-1, HSV-2 co-infected adults achieving plasma HIV RNA suppression to <50 copies/mL, between those randomized to valacyclovir and…
- Trial name
- VALIANT Pilot (NCT01176409)
- Testing
- Valacyclovir
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Herpes Simplex Type II
Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding
The investigators propose a randomized, double blind, placebo-controlled, cross-over trial to evaluate the effect of oral and topical (vaginal gel) tenofovir on genital herpes simplex virus (HSV) shedding among herpes simplex…
- Trial name
- NCT01448616
- Testing
- TDF, Vaginal TFV Gel
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Washington
Genital Herpes
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.
- Trial name
- NCT03595995
- Testing
- UB-621
- Volunteers
- 80 people
- Sponsor
- United BioPharma
Herpes Simplex Type Two Infection, HIV Infections
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a woman's risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have increased numbers of HIV "target cells" (CD4 T cells…
- Trial name
- NCT00946556
- Testing
- Valacyclovir
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
HIV/AIDS, HSV-2 Infection
The Impact of VCT and Condom Distribution as HIV Prevention Strategies Among Youth in Kenya
The vast majority of new HIV infections occur in sub-Saharan Africa, where nearly 2 million people become infected with HIV/AIDS every year.
- Trial name
- NCT03868644
- Testing
- Voluntary Counseling and Testing for HIV (VCT), Condoms
- Volunteers
- 10,646 people
- Sponsor
- Abdul Latif Jameel Poverty Action Lab
Bacterial Vaginosis, Herpes Simplex Virus Type II
Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women
We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2.
- Trial name
- NCT00682721
- Testing
- Valacyclovir
- Where
- United States
- Sponsor
- University of Pittsburgh
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record.
- Trial name
- NCT01346475
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Genital Herpes Simplex Type 2
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
This is a randomized, double-blind, factorial study to compare the reduction in viral shedding among 6 different combinations of GEN-003, a therapeutic HSV-2 vaccine and Matrix-M2 adjuvant.
- Trial name
- NCT02114060
- Testing
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg)
- Where
- 16 sites in United States
- Volunteers
- 310 people
- Sponsor
- Genocea Biosciences, Inc.